Treatment-Related Adverse Events and Health-Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review.
systematic_review · Level I
Where this comes from
- Record sourced from PubMed, PMID 42226019.
- Also identified by DOI 10.1002/hed.70306.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill-defined. Hence, known treatment-related adverse events (TRAEs) and health-related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care services. Scoping review including 98 studies. Moderate-severe TRAEs occurred at < 10% incidence, with most experiencing mild impacts. Dermatologic, endocrine, pulmonary, hepatic, gastrointestinal, and constitutional complaints were reported in > 40% of studies, with most symptoms occurring during treatment. ICI monotherapy had less reported toxicity than multimodality treatments. Adding ICIs to multimodality treatment creates a minimal increase in TRAEs. HRQoL scores were low, with little change during ICI treatment. ICIs for HNSCC are generally well tolerated; however, TRAEs are common and may carry long-term functional consequences. Flexible supportive care pathways are needed to assist early detection and individualized management of functional impacts to optimize survivorship.